KPV Peptide: Evidence, Safety, and FDA Status

KPV is the tripeptide lysine-proline-valine (Lys-Pro-Val), corresponding to the three C-terminal amino acids of alpha-melanocyte-stimulating hormone (α-MSH). It is studied primarily for anti-inflammatory signaling in cells and animal models. KPV is not an FDA-approved drug, and FDA reported in 2026 that it had not identified clinical studies or human exposure data for KPV by any route.

Profile summary

Molecular identity

KPV is commonly described as the C-terminal tripeptide of α-MSH. That relationship is a sequence description, not evidence that a manufactured vial is “natural,” clinically equivalent to α-MSH, or safe for administration.

Research materials may differ by terminal chemistry, salt form, counterion content, formulation, purity, aggregation, and assay. KPV free base and KPV acetate should not be treated as analytically identical descriptions. A product name alone cannot establish which material is present.

Evidence by model

Cell studies

Experiments in intestinal epithelial and immune-cell lines found that KPV uptake involved the oligopeptide transporter PepT1. Exposure was associated with reduced NF-κB and MAPK activation and lower expression or secretion of selected inflammatory mediators.

These measurements support a mechanistic hypothesis. They do not show symptom relief, mucosal remission, disease control, or safety in a person.

Animal colitis models

Free KPV and several colon-targeted delivery systems have been tested in DSS- or TNBS-induced colitis in mice and rats. Some experiments reported improved histology and inflammatory markers. Other studies placed KPV inside polymeric nanoparticles, hyaluronic-acid-functionalized particles, or hydrogels designed to release material in the colon.

The delivery platform is part of each intervention. A result from KPV-loaded nanoparticles inside a chitosan-alginate hydrogel does not establish that an ordinary capsule, topical product, nasal spray, or injectable vial will behave the same way.

Colitis-associated tumor model

In an AOM/DSS mouse model, KPV reduced inflammation-associated tumor burden in animals with intact PepT1, while the effect was absent in PepT1-knockout mice. The result did not establish human cancer prevention or treatment, and reduced inflammation did not reduce tumor burden in a separate genetic mouse model reported in the same paper.

What KPV has not been shown to do

No published human clinical trial has established that KPV:

• treats ulcerative colitis or Crohn’s disease;
• repairs the human stomach or intestinal lining;
• treats gastritis, reflux, or peptic ulcers;
• prevents or treats colorectal cancer;
• improves autoimmune disease, psoriasis, or systemic inflammation; or
• is safe and effective by oral, topical, intranasal, or injectable administration.

The detailed KPV gut-inflammation evidence guide explains how colon models became overstated as “stomach repair” claims online.

Human safety and regulatory status

FDA’s July 2026 evaluation stated that it had not identified clinical studies or human exposure data for KPV free base or KPV acetate by any route. FDA also found insufficient information to assess effectiveness, pharmacokinetics, chronic toxicity, immunogenicity, or aggregation-related risk.

The absence of adverse-event reports in the databases FDA searched does not establish safety. Without characterized exposure and systematic reporting, there may be too little use or surveillance to detect a signal.

KPV has no FDA-approved indication or approved drug product. At the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA proposed that KPV free base and KPV acetate not be placed on the section 503A Bulks List. That proposal concerns compounding eligibility; it is not an approval of KPV for any disease or route.

Research-quality checklist

For analytical or laboratory research, verify:

1. the complete sequence and terminal chemistry;
2. whether the material is free base, acetate, or another stated form;
3. identity evidence, such as mass spectrometry, separately from chromatographic purity;
4. lot-specific net peptide content rather than total vial mass;
5. related substances, residual solvents, water, counterions, and aggregation controls;
6. the exact delivery formulation used in the reference experiment; and
7. route-specific requirements instead of treating a purity percentage as evidence of sterility or administration safety.

The peptide purity-testing guide explains the analytical terms. The source directory organizes public batch-documentation signals, while the sourcing policy explains why inclusion is not an endorsement for human use. Use the research methodology to interpret evidence grades or the use-case map to compare claim categories without treating preclinical signals as clinical outcomes.

References

1. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.
2. Laroui H, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010.
3. Xiao B, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles. Molecular Therapy. 2017.
4. Viennois E, et al. PepT1 and KPV in a murine model of colitis-associated cancer. Cellular and Molecular Gastroenterology and Hepatology. 2016.
5. US Food and Drug Administration. KPV-related bulk drug substances: safety and effectiveness review. 2026.

Bottom line

KPV has a consistent preclinical signal in intestinal inflammation research, especially in PepT1-related cell experiments and animal colitis models. Human benefit, exposure, dosing, and safety remain unestablished. Research conclusions should preserve the exact compound, formulation, route, and model used rather than converting mechanistic findings into treatment claims.